Joel Negin, Ph.D., Philip Alpers, Natasha Nassar, Ph.D., and David Hemenway, Ph.D.
doi : 10.1056/NEJMp2102574
N Engl J Med 2021; 384:1581-1583
Benjamin A. Barsky, J.D., M.B.E., Eric Reinhart, B.A., Paul Farmer, M.D., Ph.D., and Salmaan Keshavjee, M.D., Ph.D.
doi : 10.1056/NEJMp2100609
N Engl J Med 2021; 384:1583-1585
Kushal T. Kadakia, M.Sc., Adam L. Beckman, B.S., Joseph S. Ross, M.D., M.H.S., and Harlan M. Krumholz, M.D.
doi : 10.1056/NEJMp2034518
N Engl J Med 2021; 384:e61
Daniel B. Kramer, M.D., M.P.H., Douglas J. Opel, M.D., M.P.H., Efthimios Parasidis, J.D., M.B.E., and Michelle M. Mello, J.D., Ph.D.
doi : 10.1056/NEJMp2102146
N Engl J Med 2021; 384:e62
Glenn M. Chertow, M.D., M.P.H., Pablo E. Pergola, M.D., Ph.D., Youssef M.K. Farag, M.D., Ph.D., M.P.H., Rajiv Agarwal, M.D., Susan Arnold, M.B., B.Ch., M.Med., Gabriel Bako, M.D., Geoffrey A. Block, M.D., Steven Burke, M.D., Fausto P. Castillo, M.D., Alan G. Jardine, M.B., Ch.B., M.D., Zeeshan Khawaja, M.D., Mark J. Koury, M.D., Eldrin F. Lewis, M.D., M.P.H., Tim Lin, Ph.D., Wenli Luo, Ph.D., Bradley J. Maroni, M.D., Kunihiro Matsushita, M.D., Ph.D., Peter A. McCullough, M.D., Ph.D., Patrick S. Parfrey, M.B., B.Ch., Prabir Roy-Chaudhury, M.D., Ph.D., Mark J. Sarnak, M.D., Amit Sharma, M.D., Bruce Spinowitz, M.D., Carol Tseng, Ph.D., James Tumlin, M.D., Dennis L. Vargo, M.D., Kimberly A. Walters, Ph.D., Wolfgang C. Winkelmayer, M.D., M.P.H., Sc.D., Janet Wittes, Ph.D., and Kai-Uwe Eckardt, M.D. for the PRO2TECT Study Group*
doi : 10.1056/NEJMoa2035938
N Engl J Med 2021; 384:1589-1600
Vadadustat is an oral hypoxia-inducible factor (HIF) prolyl hydroxylase inhibitor, a class of drugs that stabilize HIF and stimulate erythropoietin and red-cell production.
Kai-Uwe Eckardt, M.D., Rajiv Agarwal, M.D., Ahmad Aswad, M.D., Ahmed Awad, M.D., Geoffrey A. Block, M.D., Marcelo R. Bacci, M.D., Youssef M.K. Farag, M.D., Ph.D., M.P.H., Steven Fishbane, M.D., Harold Hubert, M.D., Alan Jardine, M.B., Ch.B., M.D., Zeeshan Khawaja, M.D., Mark J. Koury, M.D., Bradley J. Maroni, M.D., Kunihiro Matsushita, M.D., Ph.D., Peter A. McCullough, M.D., M.P.H., Eldrin F. Lewis, M.D., M.P.H., Wenli Luo, Ph.D., Patrick S. Parfrey, M.B., B.Ch., Pablo Pergola, M.D., Ph.D., Mark J. Sarnak, M.D., Bruce Spinowitz, M.D., James Tumlin, M.D., Dennis L. Vargo, M.D., Kimberly A. Walters, Ph.D., Wolfgang C. Winkelmayer, M.D., Janet Wittes, Ph.D., Rafal Zwiech, M.D., and Glenn M. Chertow, M.D., M.P.H.
doi : 10.1056/NEJMoa2025956
N Engl J Med 2021; 384:1601-1612
Vadadustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor, a class of compounds that stimulate endogenous erythropoietin production.
Gregory K. Friedman, M.D., James M. Johnston, M.D, Asim K. Bag, M.B., B.S., M.D., Joshua D. Bernstock, M.D., Ph.D., M.P.H., Rong Li, M.D., Ph.D., Inmaculada Aban, Ph.D., Kara Kachurak, C.R.N.P., Li Nan, B.S., Kyung-Don Kang, Ph.D., Stacie Totsch, Ph.D., Charles Schlappi, M.D., Allison M. Martin, M.D., Devang Pastakia, M.D., Rene McNall-Knapp, M.D., Sameer Farouk Sait, M.D., Yasmin Khakoo, M.D., Matthias A. Karajannis, M.D., Karina Woodling, M.D., C.C.R.P., Joshua D. Palmer, M.D., Diana S. Osorio, M.D., M.P.H., Jeffrey Leonard, M.D., Mohamed S. Abdelbaki, M.D., Avi Madan-Swain, Ph.D., T. Prescott Atkinson, M.D., Ph.D., Richard J. Whitley, M.D., John B. Fiveash, M.D., James M. Markert, M.D., M.P.H., and G. Yancey Gillespie, Ph.D.
doi : 10.1056/NEJMoa2024947
N Engl J Med 2021; 384:1613-1622
Outcomes in children and adolescents with recurrent or progressive high-grade glioma are poor, with a historical median overall survival of 5.6 months. Pediatric high-grade gliomas are largely immunologically silent or “cold,” with few tumor-infiltrating lymphocytes. Preclinically, pediatric brain tumors are highly sensitive to oncolytic virotherapy with genetically engineered herpes simplex virus type 1 (HSV-1) G207, which lacks genes essential for replication in normal brain tissue.
Loïc Sentilhes, M.D., Ph.D., Marie V. Sénat, M.D., Ph.D., Maëla Le Lous, M.D., Norbert Winer, M.D., Ph.D., Patrick Rozenberg, M.D., Ph.D., Gilles Kayem, M.D., Ph.D., Eric Verspyck, M.D., Ph.D., Florent Fuchs, M.D., Ph.D., Elie Azria, M.D., Ph.D., Denis Gallot, M.D., Ph.D., Diane Korb, M.D., Raoul Desbrière, M.D., Camille Le Ray, M.D., Ph.D., Céline Chauleur, M.D., Ph.D., Fanny de Marcillac, M.D., Franck Perrotin, M.D., Ph.D., Olivier Parant, M.D., Laurent J. Salomon, M.D., Ph.D., Emilie Gauchotte, M.D., Florence Bretelle, M.D., Ph.D., Nicolas Sananès, M.D., Ph.D., Caroline Bohec, M.D., Nicolas Mottet, M.D., Ph.D., Guillaume Legendre, M.D., Ph.D., Vincent Letouzey, M.D., Ph.D., Bassam Haddad, M.D., Ph.D., Delphine Vardon, M.D., Hugo Madar, M.D., Aurélien Mattuizzi, M.D., Valérie Daniel, Pharm.D., Sophie Regueme, Ph.D., Caroline Roussillon, M.D., Antoine Benard, M.D., Ph.D., Aurore Georget, M.Sc., Astrid Darsonval, Pharm.D., and Catherine Deneux-Tharaux, M.D., Ph.D. for the Groupe de Recherche en Obstétrique et Gynécologie*
doi : 10.1056/NEJMoa2028788
N Engl J Med 2021; 384:1623-1634
Prophylactic administration of tranexamic acid has been associated with reduced postpartum blood loss after cesarean delivery in several small trials, but evidence of its benefit in this clinical context remains inconclusive.
Jessica L. Bienstock, M.D., M.P.H., Ahizechukwu C. Eke, M.D., Ph.D., and Nancy A. Hueppchen, M.D.
doi : 10.1056/NEJMra1513247
N Engl J Med 2021; 384:1635-1645
Mahroo Tajalli, M.D., and Carlos G. Wambier, M.D., Ph.D.
doi : 10.1056/NEJMicm2025081
N Engl J Med 2021; 384:1646
Adam Miller, M.D., and Jeremy Schneider, M.D.
doi : 10.1056/NEJMicm2031975
N Engl J Med 2021; 384:e63
Dorit Koren, M.D., Katherine A. Sparger, M.D., Randheer Shailam, M.D., and Peter M. Sadow, M.D., Ph.D.
doi : 10.1056/NEJMcpc2100277
N Engl J Med 2021; 384:1647-1655
Adeera Levin, M.D.
doi : 10.1056/NEJMe2103937
N Engl J Med 2021; 384:1657-1658
Winfred W. Williams, M.D.
doi : 10.1056/NEJMe2102832
N Engl J Med 2021; 384:1659-1660
Eric J. Rubin, M.D., Ph.D., Lindsey R. Baden, M.D., and Stephen Morrissey, Ph.D.
doi : 10.1056/NEJMe2107327
N Engl J Med 2021; 384:e77
Devin B. Morris, B.A., Philip A. Gruppuso, M.D., Heather A. McGee, Ph.D., Anarina L. Murillo, Ph.D., Atul Grover, M.D., Ph.D., and Eli Y. Adashi, M.D.
doi : 10.1056/NEJMsr2028487
N Engl J Med 2021; 384:1661-1668
A racially and ethnically diverse health care workforce remains a distant goal, the attainment of which is contingent on the inclusivity of the national medical student body. We examined the diversity of medical school applicants and enrollees over the past four decades with an eye toward assessing the progress made. Data on the gender and race or ethnic group of enrollees in all medical doctorate degree–granting U.S. medical schools from 1978 through 2019 were examined. The percentage of female enrollees doubled during this period, and women now constitute more than half the national medical student body. This upturn has been attributed largely to an increase by a factor of 12 in the enrollment of Asian women. The corresponding decrease in the percentage of male enrollees, most notably White men, was offset by an increase by a factor of approximately 5 in the enrollment of Asian men. The percentages of enrollees from Black, Hispanic, and other racial and ethnic groups that are underrepresented in medicine remain well below the percentages of these groups in the national Census.
doi : 10.1056/NEJMc2035819
N Engl J Med 2021; 384:1669-1671
doi : 10.1056/NEJMc2035906
N Engl J Med 2021; 384:1671-1673
doi : 10.1056/NEJMc2102972
N Engl J Med 2021; 384:1673-1677
doi : 10.1056/NEJMc2102895
N Engl J Med 2021; 384:e64
doi : 10.1056/NEJMc2101280
N Engl J Med 2021; 384:e66
آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟